Rosiglitazone Pellets

(Product under development)
Rosiglitazone PelletsRosiglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer, by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. Annual sales peaked at approximately $2.5bn in 2006, but declined after reports of adverse effects. The drug's patent expires in 2012.

Some reports have found rosiglitazone is associated with an increased risk of heart attacks, but other reports have not found a statistically significant increase. Concern about adverse effects has reduced the use of rosiglitazone despite its sustained effects on glycemic control. The drug is currently the subject of over 13,000 lawsuits against .

The drug is controversial in the U.S. Some reviewers have concluded that rosiglitazone caused more deaths than pioglitazone (Actos), and have recommended rosiglitazone be taken off the market, but an FDA Food and Drug Administration panel disagreed, and it remains on the market in the U.S., subject to significant restrictions.

From November 18, 2011 the federal government will not allow Avandia to be sold without a prescription from certified doctors. Patients will be required to be informed of the risks associated with the use of Avandia, and the drug will be required to be purchased by mail order through specified pharmacies.

However, patients currently taking rosiglitazone are advised to discuss alternative options during their next physician appointment. In the UK, Diabetes UK announced, "People currently taking all forms of the recently suspended drug Avandia (Rosiglitazone) have until 21 October to be reviewed and transferred onto an alternative treatment".

In New Zealand, rosiglitazone (Avandia) is to be withdrawn from the market before April 29, 2011 after concern about its make an elevated risk of cardiovascular events. Patients should discuss alternative treatments with their doctor as soon as possible, but to continue taking the drug in the meantime.

Available Form:
Rosiglitazone Pellets
Rosiglitazone Granules

Umang Pharmatech equipments used for production of Rosiglitazone Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.


Rosiglitazone Pellets
Systematic (IUPAC) Name
Rosiglitazone Pellets
Identifiers
Rosiglitazone Pellets
Chemical data
(RS)-5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]
thiazolidine-2,4-dione
CAS number : 122320-73-4
ATC code : A10BG02
PubChem : CID 77999
IUPHAR ligand : 1056
DrugBank : APRD00403
ChemSpider : 70383
UNII : 05V02F2KDG
KEGG : D00596
ChEBI : CHEBI:50122
ChEMBL : CHEMBL121
Formula : C18H19N3O3S
Mol. mass : 357.428 g/mol


* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
Extruder Spheronizer Email Us Umang Pharmatech
TESTIMONIAL